Evidence of human acute myeloid leukemia stem cells (AML LSCs) was first reported nearly
2 decades ago through the identification of rare subpopulations of engrafting cells in …

Abstract Nucleophosmin 1 (NPM1) is a nucleus-cytoplasmic shuttling protein which is
predominantly located in the nucleolus and exerts multiple functions, including regulation of …

The relationships between normal and leukemic stem/progenitor cells are unclear. We show
that in∼ 80% of primary human CD34+ acute myeloid leukemia (AML), two expanded …

Acute myeloid leukemia (AML) originates from self-renewing leukemic stem cells (LSCs), an
ultimate therapeutic target for AML. Here we identified T cell immunoglobulin mucin-3 (TIM …

Among acute myeloid leukemia (AML) patients with a normal karyotype (CN-AML), NPM1
and CEBPA mutations define World Health Organization 2008 provisional entities …

Our understanding of the perturbation of normal cellular differentiation hierarchies to create
tumor-propagating stem cell populations is incomplete. In human acute myeloid leukemia …

After the discovery of NPM1-mutated acute myeloid leukemia (AML) in 2005 and its
subsequent inclusion as a provisional entity in the 2008 World Health Organization …

Background Acute myeloid leukemias arise from a rare population of leukemic cells, known
as leukemic stem cells, which initiate the disease and contribute to frequent relapses …

Nucleophosmin (NPM, also known as B23, numatrin or NO38) is a ubiquitously expressed
phosphoprotein belonging to the nucleoplasmin family of chaperones. NPM is mainly …

Nucleophosmin (NPM1) mutations represent an attractive therapeutic target in acute
myeloid leukemia (AML) because they are common (∼ 30% AML), stable, and behave as a …